Cell Based Assay Market Analysis | 2022-2028

“The Cell Based Assay Market was estimated at US$ 19.3 billion in 2021 and is expected to grow at a CAGR of 6.86% during 2022-2028 to reach US$ 31.78 billion in 2028”.

Wish to get a free sample? Register Here

Market Dynamics

Introduction

Cell based assays are a method for assessing the biological and cytotoxic effects of pharmaceuticals, as well as their potency and mode of action. It is a homogeneous method for figuring out how many living and dead cells are present in a sample. Living cells are examined utilizing a variety of properties, including pharmacokinetics and pharmacodynamics, using cell-based assays.

In healthcare research and development, cell-based assays have become an adaptable tool, particularly in studies targeted at understanding certain cell functions, such as antibody function or therapeutic efficacy on a set of cells.

Market Drivers

In contrast to biochemical tests, cell-based assays provide consistent tissue-specific responses in a physiologically realistic microenvironment. The pharmaceutical and biotechnology companies are also utilizing cell-based assays as part of their lead discovery and optimization processes for drug development, which is the main driver fueling this market's expansion.

COVID-19 Impact

Additionally, the likelihood of disease outbreaks (such as COVID-19 and swine flu) increasing as well as an increase in research activities are predicted to drive market expansion. The market's expansion is additionally anticipated to be tempered by the cheap costs of labor and raw materials as well as the rising number of CROs offering drug discovery services.

Several investments/guidelines in the market have been directed in recent years, which would boost the overall market. Some of them are:

• Over the past few years, several Asian governments have intensified their attention on life science research. For instance, a public-private collaboration in Japan called the Global Health Innovative Technology (GHIT) Fund supports a range of R&D initiatives for drug discovery, including the screening of compound libraries relevant to numerous infectious diseases. The global market for cell-based assays is primarily driven by R&D spending for the discovery of novel pharmaceuticals. The World Bank believes that rising economies in Asia and the Rest of the World have spent more on R&D than developed economies in North America and Europe.

Recent Developments

The market for cell based assay is highly competitive. The market players are highly focused on mergers, expansions, and product approvals, to sustain in this market.

Below are a few key developments:

• In September 2022, as part of the initial construction phase of its new € 29 million China Biologics Testing Center, Merck, a renowned science and technology corporation, built a viral clearance (VC) laboratory. It is the first facility of its sort for Merck in China, measuring 5,000 square meters. The VC laboratory will address China's double-digit demand for VC testing services by enabling companies to undertake viral clearance studies locally from pre-clinical research to commercialization. By 2023, the VC laboratory created about 120 employees.
• In August 2022, five new Charles River Accelerator and Development Lab (CRADL) facilities opened in California and Washington, according to an announcement from Charles River Laboratories International, Inc. In important bio hubs, CRADL offers adaptable, turnkey vivarium leasing space backed by Charles River's technical and veterinary support expertise. The company is building its first facility in Seattle and adding two more sites in San Diego to better serve the areas of Sorrento Valley and Torrey Pines as a result of the recent acquisition of Explora Biolabs. Additionally, CRADL has expanded its South San Francisco facilities and opened a new site in Thousand Oaks.
• In April 2022, Charles River Laboratories International, Inc. and Valo Health, Inc. introduced Logica, a medication solution powered by artificial intelligence (AI) that instantly converts clients' biological insights into optimal preclinical assets.
• In April 2022, a leading supplier of contract vivarium research services, Explora BioLabs Holdings, Inc., was purchased by Charles River Laboratories International, Inc.
• In March 2022, the BD Rhapsody TCR/BCR Multiomic Assay, a cutting-edge set of reagents that enables researchers to more easily and thoroughly analyze critical immune system cells, was released by BD (Becton, Dickinson, and Company), a leading global medical technology company. This assay offers a tool to advance research in autoimmune disorders, immuno-oncology, and infectious diseases.
• In January 2021, Thermo Fisher Scientific purchased Phitonex, a business with headquarters in North Carolina. Phitonex has developed a spectral dye platform for high-resolution biological applications. The Phiton platform from Phitonex is intended to hasten the development of immunology, immuno-oncology, and cell therapy. The platform serves as a framework to keep a broader variety of fluorescent dyes in defined ways, enabling researchers to gather more thorough data from cell samples. Additionally, it enables scientists to swiftly produce a variety of dye labels that can be used to identify more proteins and cell types in a single experiment
• In March 2019, CellBio Services, a broad array of distinctive, tailored solutions created to address particular, unique research application demands, was announced by Lonza. Researchers working for pharmaceutical and contract manufacturing companies have access to a wide range of services, including medium preparation, cell isolation, cell characterization, transfection services, cell-line expansion and banking, and three-dimensional (3D) cell culture.

Segments Analysis

By Product & Service Type

The market is further segmented into consumables, instruments, services, and software. The consumables segment is further bifurcated into reagents and assay kits. The assay kits are further divided into reporter gene assays, cell growth assays, second messenger assays, cell death assays, and others. Based on instruments, the market is further segmented into microplates, microplate readers, high throughput screening, and liquid handling systems.

By Technology Type

The market has been divided into automated handling, flow cytometry, label-free detection, high-throughput screening, and others. To shorten the duration and increase the throughput of these investigations, cell-based assays are utilized. The demand for cell-based diagnostics that provide an early indication of the toxicity characteristics of potential therapeutic candidates has consequently surged.

Regional Analysis

“North America is expected to lead the cell-based assay market in 2021”.

The market is broken down geographically into geographies, namely North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2021, North America is anticipated to be the cell based assay market's largest region. 

The introduction of new medications and technological developments in the end-use industries for cell-based assays will create attractive market prospects. The adoption of strategic strategies including collaborations to create drug candidates and an increase in drug discovery initiatives will boost the growth rate of the cell based assay market in the future.

Key Players

The following are the key players in the Cell Based Assay Market (arranged alphabetically)

• BD
• Bio-Rad Laboratories Inc.  
• Cell Biolabs Inc.  
• Cell Signaling Technology  
• Charles River Laboratories Inc.  
• Corning Inc. 
• Eurofins DiscoverX Corporation 
• F. Hoffmann-La Roche AG
• GE Healthcare Biopharma (Danaher Corporation) 
• Lonza Group Ltd.  
• Merck Group
• PerkinElmer Inc.
• Promega Corporation  
• Thermo Fisher Scientific Inc.

The overall competitive landscape has been affected due to these mergers and acquisitions. 

Note: The above list does not necessarily include all the top players in the market.

Are you the leading player in this market? We would love to include your name. Write to us at sales@stratviewresearch.com

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research:

Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.